A Study of Participant Preference With Subcutaneous Versus Intravenous MabThera/Rituxan in Participants With CD20+ Diffuse Large B-Cell Lymphoma or CD20+ Follicular Non-Hodgkin's Lymphoma Grades 1, 2 or 3a

NCT01724021 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

743

Enrollment

INDUSTRY

Sponsor class

Conditions

Diffuse Large B-Cell Lymphoma, Non-Hodgkin's Lymphoma

Interventions

DRUG: Cyclophosphamide, Hydroxydaunorubicin, Oncovin, Prednisone/Prednisolone (CHOP)
DRUG: Cyclophosphamide, Vincristine, Prednisone/Prednisolone (CVP)
DRUG: Bendamustine
DRUG: Rituximab
DRUG: Rituximab
DRUG: Rituximab
DRUG: Rituximab

Sponsor

Hoffmann-La Roche